Brief: Resverlogix’s Betonmace Phase 3 Epigenetics Trial Completes Final Safety Visits
08/07/2019 14:27
July 8 (Reuters) - Resverlogix Corp RVX.TO :
* RESVERLOGIX’S BETONMACE PHASE 3 EPIGENETICS TRIAL
COMPLETES
FINAL SAFETY VISITS
* RESVERLOGIX CORP - ANTICIPATES BEING IN A POSITION TO
PROVIDE
TOP-LINE RESULTS IN SEPTEMBER 2019
* RESVERLOGIX’S BETONMACE PHASE 3 EPIGENETICS TRIAL
COMPLETES
FINAL SAFETY VISITS
Source text for Eikon: ID:nGNX1xZHtz
Further company coverage: RVX.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment